Clinical trials: High Grade Serous Carcinoma
Triple Negative Breast Cancer, Renal Cell Cancer
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI)…
- Conditions
- Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- ModiFY (NCT05329532)
- Testing
- Modi-1 Moditope, Pembrolizumab, MicronJet600™ microneedle device (NanoPass)
- Where
- 16 sites in United Kingdom
- Volunteers
- 168 people
- Sponsor
- Scancell Ltd
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Ovarian Neoplasms, Endometrial Neoplasms
A Study of SGN-ALPV in Advanced Solid Tumors
This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms
- Trial name
- NCT05229900
- Testing
- SGN-ALPV
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 43 people
- Sponsor
- Seagen Inc.
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
This phase II trial compares copanlisib and olaparib to standard of care chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous platinum-based chemotherapy…
- Conditions
- Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT05295589
- Testing
- Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma
PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma
Single center, phase I/II randomized 2-arm study, evaluating two different vaccination regimens combined with low-dose cyclophosphamide in patients with advanced high grade serous ovarian carcinoma (HGSOC): Arm A patients will be…
- Trial name
- CHUV-OVACURE (NCT05714306)
- Testing
- PEP-DC1, OC-DC, PEP-DC2
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma
- Trial name
- POSITION (NCT02316834)
- Testing
- Laboratory Biomarker Analysis, BMN 673
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Serous Ovarian Tumor, Endometrioid Carcinoma Ovary
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
A pilot study to evaluate the feasibility of a NGS-based tumour BRCA1/2 mutation testing pathway initiated in the oncology clinic for patients with HGSEC, either at primary diagnosis or first relapse, whereby only patients with a…
- Conditions
- Serous Ovarian Tumor, Endometrioid Carcinoma Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06274541
- Testing
- Somatic and Germline BRCA1/2 Testing
- Where
- 5 sites in Ireland
- Volunteers
- 200 people
- Sponsor
- Cancer Trials Ireland
Appendix Cancer, Pseudomyxoma Peritonei
The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
ACPMP's first-ever patient-powered global patient registry/natural history study collects patient and caregiver information and data to fuel clinical trials and drive breakthroughs for appendix cancer and PMP.
- Trial name
- NCT07769346
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Appendix Cancer Pseudomyxoma Peritonei Research Foundation
High Grade Serous Carcinoma, Triple Negative Breast Cancer
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
The purpose of this Phase I study is to determine if the PARP inhibitor olaparib can be safely combined with navitoclax, an inhibitor of Bcl-2/Bcl-XL, in women with TNBC who have somatic or germline mutations in breast cancer…
- Conditions
- High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
- Trial name
- NCT05358639
- Testing
- Olaparib tablet, Navitoclax
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Sunnybrook Health Sciences Centre
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT03943173
- Testing
- Chemotherapy, Olaparib, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
The goal of this project is to develop a minimally invasive test to detect ovarian cancer, by searching for mutations from the tumor in samples obtained from the cervix (Pap smears), and from the uterus (uterine lavage) in…
- Conditions
- High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8
- Trial name
- NCT03606486
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis, Lavage
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Washington
Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
Pancreatic, ovarian and colorectal cancers are difficult to treat using chemotherapy and immune therapies.Currently most patients are offered treatment with a standard chemotherapy drug depending on their cancer type.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- CAM-PLEX (NCT02179970)
- Testing
- Plerixafor
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- CCTU- Cancer Theme
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum…
- Trial name
- NCT02098343
- Testing
- APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Where
- 55 sites in United States, Belgium and 6 more
- Volunteers
- 247 people
- Sponsor
- Aprea Therapeutics
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
- Conditions
- Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- PRESERVE-004 (NCT05446298)
- Testing
- ONC-392, Pembrolizumab
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- OncoC4, Inc.
Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian…
- Conditions
- Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04585958
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Serous Ovarian Cancer
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma
Background and rationale of the study: From our preliminary analyses of a dataset on patients with high-grade serous ovarian carcinoma (HGSOC), available in the online database The Cancer Genome Atlas, we found that the gene…
- Trial name
- OVCAR (NCT06777082)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
BRCA1 Mutation, BRCA2 Mutation
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Ovarian cancer is the most fatal gynecologic cancer; in the US alone an estimated 22,000 women will be diagnosed in 2019, with over 13,000 dying of the disease.
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT04598321
- Testing
- Talazoparib Oral Capsule
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
- Trial name
- DUAL-OV-CAR-NK (NCT07480954)
- Testing
- Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech